Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomics of High dose of TCM in osteoporosis rat

ABSTRACT: Proteomics of High dose of TCM，model and normal in rat

ORGANISM(S): Rattus Rattus

SUBMITTER: Naiqiang Zhu

PROVIDER: PXD050293 | iProX | Sun Mar 03 00:00:00 GMT 2024

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

Transcription profiling of rat right heart pulmonary embolism vs control

Project description:Time and dose related expression profiles of rat right heart tissue in microsphere bead model for Pulmonary embolism Experiment Overall Design: Rat right tissues of the Vehicle(no beads- control), low dose and high dose from rat bead model for Pulmonary Embolism were collected after 2, 6 and 18 hour time points. The extracted RNA was hybridized to Affymetrix Rat 230-2.0 microarrays to look for the dose and/or time related transcriptional changes associated with experimental Pulmonary Embolism.

2008-10-18 | E-GEOD-6104 | biostudies-arrayexpress

Biological Responses During High-dose Protein Nutrition

Project description:Biological Responses During High-dose Protein Nutrition

| PRJNA1269929 | ENA

High-dose isoproterenol induced cardiac immune responses

Project description:High-dose isoproterenol induced cardiac immune responses

| PRJNA782647 | ENA

T-cells' gene expression after high-dose melphalan

Project description:T-cells' gene expression after high-dose melphalan

| PRJNA625689 | ENA

Metabolic responses of normal rat kidneys to a high salt intake

Project description:Metabolic responses of normal rat kidneys to a high salt intake

| PRJNA933229 | ENA

Rat right heart pulmonary embolism microarray

Project description:Time and dose related expression profiles of rat right heart tissue in microsphere bead model for Pulmonary embolism Keywords: Time course and dose response in experimental PE

2008-07-01 | GSE6104 | GEO

High-dose Ascorbic acid synergizes with anti-PD1 in a Lymphoma mouse model

Project description:High-dose Ascorbic acid synergizes with anti-PD1 in a Lymphoma mouse model

| PRJNA593511 | ENA

High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model

Project description:High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model

| PRJNA593266 | ENA

Expression data from cerivastatin-treated rat skeletal muscle

Project description:Adverse effects of statins include skeletal muscle toxicity; Type II glycolytic fibers are more senstive to statin damage; exercise exacerbates statin muscle degeneration. We used a well-characterized rat model of statin-induced muscle degeneration, at which 1.0 mg/kg/day (high dose) cerivastatin produces mild to moderate histological degeneration. We used microarrays to detail the global programme of gene expression underlying cerivastatin effects on rat gastrocnemius and soleus muscles, as well as the effect of cerivastatin combined with treadmill exercise. We identified distinct classes of up- and down-regulated genes during this process. Keywords: dose response; exercise effect

2007-03-05 | GSE4418 | GEO

Gene expression profile of hepatocellular carcinoma in low-dose, repeated diethylnitrosamine (DEN)-treated rat treated with erlotinib

Project description:Gene-expression profiles of rat hepatocellular carcinoma induced by diethylnitrosamine (DEN) and the effect of erlotinib Hepatocellular carcinoma (HCC) is the sixth most common solid tumor worldwide and the third leading cause of cancer-related death. Given the lack of successful treatment options, chemoprevention in high-risk patients has been proposed as an alternative strategy. Mounting evidence supports a role for epidermal growth factor (EGF) during chronic liver disease and hepatocellular transformation. We address the hypothesis that blocking the EGF-EGF receptor (EGFR) pathway may be an effective strategy for inhibiting fibrogenesis and hepatocarcinogenesis. A rat model of diethylnitrosamine (DEN)-induced cirrhosis was used to examine the effects of erlotinib on underlying chronic liver disease and HCC formation. The DEN-induced rat model closely resembles disease progression in humans both pathologically and molecularly. Erlotinib significantly prevented the development of HCC tumor nodules in a dose-dependent fashion. Further, erlotinib inhibited the activation of hepatic stellate cells and prevented fibrogenesis. Erlotinib also reduced hepatotoxicity and improved liver function. Finally, a gene expression signature predictive of poor survival in human cirrhosis patients was reversed in response to erlotinib. Our data demonstrate for the first time that EGFR inhibition prevents liver fibrogenesis. Further, our results suggest that erlotinib is a potentially effective HCC chemoprevention strategy through inhibition of cirrhosis progression which can be monitored at the molecular level.

2014-02-28 | GSE27638 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data